

# Minoru Fukuda

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/4943247/minoru-fukuda-publications-by-year.pdf>

**Version:** 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

62 papers	584 citations	11 h-index	21 g-index
69 ext. papers	690 ext. citations	3 avg, IF	2.77 L-index

#	Paper	IF	Citations
62	A Case of Advanced Thymic Carcinoma in Which Carboplatin and Nab-paclitaxel Were Significantly Effective After Progression on Lenvatinib. <i>Japanese Journal of Lung Cancer</i> , <b>2022</b> , 62, 115-120	0.1	0
61	The role of comprehensive analysis with circulating tumor DNA in advanced non-small cell lung cancer patients considered for osimertinib treatment. <i>Cancer Medicine</i> , <b>2021</b> , 10, 3873-3885	4.8	2
60	Dabrafenib and trametinib therapy in an elderly patient with non-small cell lung cancer harboring the BRAF V600E mutation. <i>Thoracic Cancer</i> , <b>2021</b> , 12, 272-276	3.2	1
59	Remarkable response to pembrolizumab with platinum-doublet in PD-L1-low pulmonary sarcomatoid carcinoma: A case report. <i>Thoracic Cancer</i> , <b>2021</b> , 12, 1126-1130	3.2	2
58	Efficacy of S-1 after pemetrexed in patients with non-small cell lung cancer: A retrospective multi-institutional analysis. <i>Thoracic Cancer</i> , <b>2021</b> , 12, 2300-2306	3.2	1
57	Tracheal Paraganglioma: A Case report and Review of the Pertinent Literature. <i>Internal Medicine</i> , <b>2021</b> , 60, 2275-2283	1.1	0
56	A Phase II Study of Osimertinib for Radiotherapy-Naïve Central Nervous System Metastasis From NSCLC: Results for the T790M Cohort of the OCEAN Study (LOGIK1603/WJOG9116L). <i>Journal of Thoracic Oncology</i> , <b>2021</b> , 16, 2121-2132	8.9	5
55	A novel automated immunoassay for serum NY-ESO-1 and XAGE1 antibodies in combinatory prediction of response to anti-programmed cell death-1 therapy in non-small-cell lung cancer. <i>Clinica Chimica Acta</i> , <b>2021</b> , 519, 51-59	6.2	2
54	Real-World Incidence of Febrile Neutropenia among Patients Treated with Single-Agent Amrubicin: Necessity of the Primary Prophylactic Administration of Granulocyte Colony-Stimulating Factor. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,	5.1	1
53	A phase II study of Osimertinib for patients with radiotherapy-naïve CNS metastasis of non-small cell lung cancer: treatment rationale and protocol design of the OCEAN study (LOGIK 1603/WJOG 9116L). <i>BMC Cancer</i> , <b>2020</b> , 20, 370	4.8	4
52	Final Results from a Phase II Trial of Osimertinib for Elderly Patients with Epidermal Growth Factor Receptor t790m-Positive Non-Small Cell Lung Cancer That Progressed during Previous Treatment. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	5.1	3
51	Amrubicin in previously treated patients with malignant pleural mesothelioma: A phase II study. <i>Thoracic Cancer</i> , <b>2020</b> , 11, 1972-1978	3.2	3
50	S-1 plus cisplatin with concurrent radiotherapy for locally advanced thymic carcinoma: Study protocol of LOGIK1605/JART-1501. <i>Thoracic Cancer</i> , <b>2020</b> , 11, 693-696	3.2	3
49	Prospective study for usefulness of circulating-free DNA on prediction of third generation EGFR tyrosine kinase inhibitors.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, e21510-e21510	2.2	
48	A phase II study of osimertinib for patients with radiotherapy-naïve CNS metastasis of non-small cell lung cancer harboring EGFR mutations: The OCEAN study (LOGIK 1603/WJOG 9116L).. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 9597-9597	2.2	0
47	Phase II study of ramucirumab and docetaxel for previously treated non-small cell lung cancer patients with malignant pleural effusion: Protocol of PLEURAM study. <i>Thoracic Cancer</i> , <b>2020</b> , 11, 389-393	3.2	1
46	Prediction of Anti-Cancer Drug-Induced Pneumonia in Lung Cancer Patients: Novel High-Resolution Computed Tomography Fibrosis Scoring. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	5.1	1

45	Dose escalation study of amrubicin and cisplatin with concurrent thoracic radiotherapy for limited-disease small cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2019</b> , 84, 1059-1064	3.5	1
44	Serum Antibody Against NY-ESO-1 and XAGE1 Antigens Potentially Predicts Clinical Responses to Anti-Programmed Cell Death-1 Therapy in NSCLC. <i>Journal of Thoracic Oncology</i> , <b>2019</b> , 14, 2071-2083	8.9	18
43	Osimertinib in Elderly Patients with Epidermal Growth Factor Receptor T790M-Positive Non-Small-Cell Lung Cancer Who Progressed During Prior Treatment: A Phase II Trial. <i>Oncologist</i> , <b>2019</b> , 24, 593-e170	5.7	8
42	Randomized phase II study of pemetrexed or pemetrexed plus bevacizumab for elderly patients with previously untreated non-squamous non-small cell lung cancer: Results of the Lung Oncology Group in Kyushu (LOGIK1201). <i>Lung Cancer</i> , <b>2019</b> , 132, 1-8	5.9	6
41	Clinical and computed tomography characteristics of non-small cell lung cancer with ALK gene rearrangement: Comparison with EGFR mutation and ALK/EGFR-negative lung cancer. <i>Thoracic Cancer</i> , <b>2019</b> , 10, 872-879	3.2	5
40	Phase II study of nedaplatin and amrubicin as first-line treatment for advanced squamous cell lung cancer. <i>Thoracic Cancer</i> , <b>2019</b> , 10, 1764-1769	3.2	2
39	Serum NY-ESO-1 and XAGE1 antibodies as predictive biomarkers in anti-PD-1 therapy for non-small-cell lung cancer.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 106-106	2.2	
38	Carcinoembryonic antigen (CEA) as a candidate prognostic marker of nonmucinous pneumonic adenocarcinoma (P-ADC) of the lung. <b>2019</b> , 5, 28-28		
37	Phase II trial of a non-platinum triplet for patients with advanced non-small cell lung carcinoma (NSCLC) overexpressing ERCC1 messenger RNA. <i>Thoracic Cancer</i> , <b>2019</b> , 10, 452-458	3.2	4
36	Clinical significance of humoral immunity against XAGE1 cancer-testis antigen in lung adenocarcinoma.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 162-162	2.2	1
35	Relationship between UGT1A1*27 and UGT1A1*7 polymorphisms and irinotecan-related toxicities in patients with lung cancer. <i>Thoracic Cancer</i> , <b>2018</b> , 9, 51-58	3.2	6
34	Pulmonary pleomorphic carcinoma with few PD-1-positive immune cells and regulatory T cells that showed a complete response to nivolumab. <i>Thoracic Cancer</i> , <b>2018</b> , 9, 193-196	3.2	13
33	Diffuse alveolar hemorrhage with pseudoprogression during nivolumab therapy in a patient with malignant melanoma. <i>Thoracic Cancer</i> , <b>2018</b> , 9, 1522-1524	3.2	7
32	Phase I study of irinotecan for previously treated lung cancer patients with the UGT1A1*28 or *6 polymorphism: Results of the Lung Oncology Group in Kyushu (LOGIK1004A). <i>Thoracic Cancer</i> , <b>2017</b> , 8, 40-45	3.2	3
31	Adverse renal effects of anaplastic lymphoma kinase inhibitors and the response to alectinib of an ALK+ lung cancer patient with renal dysfunction. <i>OncoTargets and Therapy</i> , <b>2017</b> , 10, 3211-3214	4.4	8
30	Phase I study of pemetrexed and concurrent radiotherapy for previously untreated elderly patients with locally advanced non-squamous non-small cell lung cancer. <i>Thoracic Cancer</i> , <b>2017</b> , 8, 577-581	3.2	5
29	Phase I study of amrubicin and cisplatin with concurrent thoracic radiotherapy (TRT) in limited-disease small cell lung cancer (LD-SCLC).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, e20023-e20023	2.2	
28	Pharmacokinetic parameters of gefitinib predict efficacy and toxicity in patients with advanced non-small cell lung cancer harboring EGFR mutations. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2016</b> , 78, 377-82	3.5	6

27	A Phase II Study of S-1 for Previously Untreated Elderly Patients with Advanced Non-Small Cell Lung Cancer. <i>Chemotherapy</i> , <b>2016</b> , 61, 93-8	3.2	9
26	Drug fever after cancer chemotherapy is most commonly observed on posttreatment days 3 and 4. <i>Supportive Care in Cancer</i> , <b>2016</b> , 24, 615-619	3.9	10
25	Prospective study of the UGT1A1*27 gene polymorphism during irinotecan therapy in patients with lung cancer: Results of Lung Oncology Group in Kyusyu (LOGIK1004B). <i>Thoracic Cancer</i> , <b>2016</b> , 7, 467-72	3.2	10
24	Randomized feasibility study of S-1 for adjuvant chemotherapy in completely resected Stage IA non-small-cell lung cancer: results of the Setouchi Lung Cancer Group Study 0701. <i>Japanese Journal of Clinical Oncology</i> , <b>2016</b> , 46, 741-7	2.8	7
23	A phase II study of amrubicin and carboplatin for previously untreated patients with extensive-disease small cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2014</b> , 74, 497-502	3.5	4
22	Phase I/II study of amrubicin and nedaplatin in patients with untreated, advanced, non-small cell lung cancer. <i>Chemotherapy</i> , <b>2014</b> , 60, 180-4	3.2	2
21	Pharmacokinetic parameters of gefitinib predicts its progression-free survival and adverse events.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, e19038-e19038	2.2	0
20	Which do patients prefer as a first-line therapy, EGFR-TKI or chemotherapy, if they have NSCLC harboring EGFR mutation? A Vignettes study (LOGIK0903).. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, e19016-e19016	2.2	2
19	Phase I and II trials of vinorelbine with carboplatin for patients 75 years of age or older with previously untreated non-small-cell lung cancer. <i>Clinical Lung Cancer</i> , <b>2012</b> , 13, 347-51	4.9	4
18	Phase II study of irinotecan and cisplatin with concurrent split-course radiotherapy in limited-disease small cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2012</b> , 70, 645-51	3.5	9
17	Phase I/II study of amrubicin and nedaplatin in patients with untreated, advanced non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 7569-7569	2.2	
16	Randomized phase II trial of irinotecan with paclitaxel or gemcitabine for non-small cell lung cancer: association of UGT1A1*6 and UGT1A1*27 with severe neutropenia. <i>Journal of Thoracic Oncology</i> , <b>2011</b> , 6, 121-7	8.9	23
15	Pharmacokinetics of gefitinib predicts antitumor activity for advanced non-small cell lung cancer. <i>Journal of Thoracic Oncology</i> , <b>2010</b> , 5, 1404-9	8.9	42
14	Efficacy and safety of amrubicin hydrochloride for treatment of relapsed small cell lung cancer. <i>Cancer Management and Research</i> , <b>2010</b> , 2, 191-5	3.6	8
13	A phase I study of amrubicin and carboplatin for previously untreated patients with extensive-disease small cell lung cancer. <i>Journal of Thoracic Oncology</i> , <b>2009</b> , 4, 741-5	8.9	11
12	Irinotecan and cisplatin with concurrent split-course radiotherapy in locally advanced nonsmall-cell lung cancer: a multiinstitutional phase 2 study. <i>Cancer</i> , <b>2007</b> , 110, 606-13	6.4	10
11	Paclitaxel and cisplatin with concurrent radiotherapy followed by surgery in locally advanced thymic carcinoma. <i>Anticancer Research</i> , <b>2007</b> , 27, 1601-4	2.3	2
10	A phase I trial of carboplatin and etoposide for elderly (>or=75 year-old) patients with small-cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2006</b> , 58, 601-6	3.5	12

9	Both bronchial and vascular stenting followed by chemoradiotherapy for locally advanced non-small cell lung cancer. <i>Anticancer Research</i> , <b>2006</b> , 26, 565-7	2.3	3
8	Community-acquired pneumonia in Japan: a prospective ambulatory and hospitalized patient study. <i>Journal of Medical Microbiology</i> , <b>2005</b> , 54, 395-400	3.2	72
7	Outbreak of <i>Chlamydophila pneumoniae</i> infection in long-term care facilities and an affiliated hospital. <i>Journal of Medical Microbiology</i> , <b>2005</b> , 54, 1243-1247	3.2	8
6	High-risk populations for nasal carriage of methicillin-resistant <i>Staphylococcus aureus</i> . <i>Journal of Infection and Chemotherapy</i> , <b>2004</b> , 10, 189-91	2.2	10
5	Phase II study of irinotecan combined with carboplatin in previously untreated non-small-cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2004</b> , 54, 573-7	3.5	23
4	Bronchoscopic therapy for mucosa-associated lymphoid tissue lymphoma of the trachea. <i>Internal Medicine</i> , <b>1999</b> , 38, 276-8	1.1	13
3	Prospective evaluation of the feasibility of cisplatin-based chemotherapy for elderly lung cancer patients with normal organ functions. <i>Japanese Journal of Cancer Research</i> , <b>1995</b> , 86, 1198-202		71
2	IgM neutralizing antibody responses to human herpesvirus-6 in patients with exanthem subitum or organ transplantation. <i>Microbiology and Immunology</i> , <b>1992</b> , 36, 495-506	2.7	46
1	Autotransplantation of peripheral blood stem cells mobilized by chemotherapy and recombinant human granulocyte colony-stimulating factor in childhood neuroblastoma and non-Hodgkin's lymphoma. <i>British Journal of Haematology</i> , <b>1992</b> , 80, 327-31	4.5	47